SHELLY RANCK: Open Payments
NPI 1457320954 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,382 in 46 payments from 13 companies in 2025. Trend: 2023 $845 · 2024 $1,395 · 2025 $1,382
Food & beverage: $1,382
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 14 | $330 |
| GENZYME CORPORATION | 5 | $255 |
| Janssen Biotech, Inc. | 7 | $206 |
| Ardelyx, Inc. | 3 | $141 |
| Lilly USA, LLC | 1 | $122 |
| Gilead Sciences, Inc. | 4 | $84 |
| ABBVIE INC. | 3 | $62 |
| Regeneron Healthcare Solutions, Inc. | 3 | $60 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $47 |
| Ipsen Biopharmaceuticals, Inc | 1 | $27 |
Products named: REZDIFFRA, DUPIXENT, TREMFYA, IBSRELA, OMVOH, XIFAXAN, RINVOQ, IQIRVO.
Industry payments across NE — which companies pay providers there.
